It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.

 

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Code Company Price % Six Month % Month % Week Market Cap
TSN The Sust Nutri Grp 0.26 -46 -10 24 $ 25,247,660.10
RNO Rhinomed Ltd 0.25 52 -19 11 $ 63,452,283.00
PIQ Proteomics Int Lab 1.05 -7 21 11 $ 105,655,875.00
VHT Volpara Health Tech 1.1825 -3 -6 11 $ 275,231,623.70
PBP Probiotec Limited 2.22 13 3 10 $ 161,634,616.36
ADR Adherium Ltd 0.013 -24 0 8 $ 25,538,971.82
TLX Telix Pharmaceutical 7.05 76 22 8 $ 2,018,316,188.64
IRX Inhalerx Limited 0.1 5 -5 8 $ 16,846,695.70
4DX 4Dmedical Limited 1.37 7 1 7 $ 289,403,731.76
RAP Resapp Health Ltd 0.059 5 -9 5 $ 49,833,430.47
SDI SDI Limited 1.09 28 7 5 $ 129,563,427.70
RHT Resonance Health 0.11 -42 -4 5 $ 50,693,717.91
VBS Vectus Biosystems 1.45 49 -24 5 $ 48,170,224.52
MEM Memphasys Ltd 0.1 79 56 4 $ 72,880,407.00
BIT Biotron Limited 0.05 -2 -2 4 $ 35,096,635.65
CYC Cyclopharm Limited 1.925 -25 -8 4 $ 179,746,534.28
EYE Nova EYE Medical Ltd 0.395 23 -4 4 $ 55,310,440.58
ICR Intelicare Holdings 0.1 -60 7 4 $ 4,648,720.50
BDX Bcaldiagnostics 0.15 -3 3 $ 19,728,984.30
IPD Impedimed Limited 0.18 44 6 3 $ 310,767,187.85
PSQ Pacific Smiles Grp 3.01 20 4 3 $ 475,554,175.24
ATX Amplia Therapeutics 0.19 -17 -2 3 $ 29,469,197.79
SOM SomnoMed Limited 2.37 7 -2 3 $ 195,311,983.40
EZZ EZZ Life Science 0.49 0 -3 2 $ 5,880,000.00
BWX BWX Limited 4.5 -13 -6 2 $ 732,040,959.65
HCT Holista CollTech Ltd 0.054 2 -10 2 $ 14,318,152.52
PGC Paragon Care Limited 0.285 21 -8 2 $ 100,149,199.22
MMJ MMJ Group Hlds Ltd 0.067 -14 -8 2 $ 15,636,870.98
ARX Aroa Biosurgery 1.15 -1 -2 1 $ 391,432,924.32
1AD Adalta Limited 0.086 -36 1 1 $ 21,125,465.10
ONT 1300 Smiles Limited 7.13001 16 0 1 $ 168,827,114.70
OVN Oventus Medical Ltd 0.099 -18 -16 1 $ 23,930,926.97
IHL Incannex Healthcare 0.565 109 59 1 $ 682,818,321.70
TRP Tissue Repair 0.62 $ 27,741,395.18
RAD Radiopharm 0 $ -
SCU Stemcell United Ltd 0.014 -26 0 0 $ 14,606,489.21
S66 Star Combo 0.28 10 -5 0 $ 37,719,491.32
RSH Respiri Limited 0.059 -41 -12 0 $ 42,647,606.61
RGS Regeneus Ltd 0.071 -27 -3 0 $ 21,757,020.89
PYC PYC Therapeutics 0.145 -3 0 0 $ 493,043,545.97
PAL Palla Pharma Ltd 0.395 -1 16 0 $ 63,955,699.39
NEU Neuren Pharmaceut. 1.78 47 -6 0 $ 225,478,560.04
MEB Medibio Limited 0.007 0 -13 0 $ 12,565,430.49
ICS ICSGlobal Limited 0.575313 -1 0 0 $ 6,054,604.94
FFC Farmaforce Ltd 0.055 -31 8 0 $ 7,187,453.90
CMP Compumedics Limited 0.35 -15 -10 0 $ 61,121,217.06
BXN Bioxyne Ltd 0.022 5 -19 0 $ 15,363,489.55
ALT Analytica Limited 0.002 0 0 0 $ 9,227,602.26
AHK Ark Mines Limited 0.034 0 0 0 $ 1,778,919.95
MVP Medical Developments 4.9 -2 0 0 $ 354,898,066.56
NXS Next Science Limited 1.255 -25 2 0 $ 252,416,733.98
UBI Universal Biosensors 0.91 32 21 -1 $ 158,199,144.72
LDX Lumos Diagnostics 0.78 -15 -1 $ 125,606,536.65
CYP Cynata Therapeutics 0.535 -9 -11 -1 $ 75,936,594.82
LBT LBT Innovations 0.098 20 -11 -1 $ 27,465,940.58
GLH Global Health Ltd 0.41 -44 14 -1 $ 23,209,850.72
MDR Medadvisor Limited 0.39 30 5 -1 $ 145,332,608.96
TRU Truscreen 0.075 4 0 -1 $ 27,214,968.98
HXL Hexima 0.365 128 -3 -1 $ 52,389,123.79
CTE Cryosite Limited 0.355 -1 4 -1 $ 17,327,394.87
MVF Monash IVF Group Ltd 0.92 12 -3 -2 $ 366,256,749.60
CDY Cellmid Limited 0.061 -5 -8 -2 $ 13,433,264.15
RCE Recce Pharmaceutical 0.855 -18 -8 -2 $ 148,588,609.19
NYR Nyrada Inc. 0.235 -20 0 -2 $ 28,882,169.05
PCK Painchek Ltd 0.046 -32 -15 -2 $ 53,194,825.55
OSX Osteopore Limited 0.225 -55 -17 -2 $ 26,385,353.55
ADO Anteotech Ltd 0.205 -41 -18 -2 $ 414,102,508.26
PAB Patrys Limited 0.039 45 -2 -3 $ 74,269,178.84
PAR Paradigm Bio. 2.16 -11 14 -3 $ 493,087,209.93
NSB Neuroscientific 0.36 18 -13 -3 $ 52,367,149.70
OCC Orthocell Limited 0.52 2 -6 -3 $ 101,057,742.24
1ST 1St Group Ltd 0.0145 -25 -9 -3 $ 7,052,862.98
CAN Cann Group Ltd 0.285 -36 -8 -3 $ 99,423,533.36
AHC Austco Healthcare 0.14 43 -3 -3 $ 39,786,453.14
M7T Mach7 Tech Limited 0.9 -15 -9 -4 $ 224,235,317.25
GSS Genetic Signatures 1.24 3 -17 -4 $ 183,163,194.88
TD1 Tali Digital Limited 0.024 -35 -14 -4 $ 23,297,644.73
IMC Immuron Limited 0.12 -27 -4 -4 $ 27,309,551.52
CAJ Capitol Health 0.355 -1 -4 -4 $ 383,319,079.44
NOX Noxopharm Limited 0.465 -17 -13 -4 $ 140,274,216.00
BNO Bionomics Limited 0.11 -44 -12 -4 $ 111,935,641.84
CBL Control Bionics 0.43 -28 -26 -4 $ 20,384,016.93
ZNO Zoono Group Ltd 0.405 -42 -14 -5 $ 66,951,646.34
OIL Optiscan Imaging 0.2 -51 -7 -5 $ 123,637,120.40
MX1 Micro-X Limited 0.3 -6 -6 -5 $ 128,835,768.60
PNV Polynovo Limited 1.465 -45 -21 -5 $ 939,171,022.48
OPT Opthea Limited 1.175 -22 -8 -5 $ 416,159,296.80
BOT Botanix Pharma Ltd 0.059 -21 -5 -6 $ 56,442,240.29
ALC Alcidion Group Ltd 0.335 -6 -3 -6 $ 351,103,132.42
CGS Cogstate Ltd 2.26 181 1 -6 $ 400,435,860.48
AVE Avecho Biotech Ltd 0.016 -6 -6 -6 $ 30,295,922.68
RAC Race Oncology Ltd 3.29 0 3 -6 $ 563,783,828.14
OSL Oncosil Medical 0.046 -43 -10 -6 $ 35,655,448.23
VTI Vision Tech Inc 0.915 -24 -4 -6 $ 21,862,837.50
MXC Mgc Pharmaceuticals 0.045 -12 -10 -6 $ 110,588,409.33
PXS Pharmaxis Ltd 0.1075 34 -2 -7 $ 56,434,058.56
KZA Kazia Therapeutics 1.46 18 -2 -7 $ 198,828,313.50
ILA Island Pharma 0.27 -23 -14 -7 $ 11,675,654.82
AT1 Atomo Diagnostics 0.195 11 -46 -7 $ 75,607,712.35
OSP Osprey Med Inc 0.75 -56 -18 -7 $ 19,243,906.50
ZLD Zelira Therapeutics 0.037 -20 -12 -8 $ 47,220,570.75
IDT IDT Australia Ltd 0.425 42 -24 -8 $ 98,342,669.70
DXB Dimerix Ltd 0.24 -2 -13 -8 $ 78,614,048.17
CHM Chimeric Therapeutic 0.28 -7 -11 -8 $ 62,191,888.32
NC6 Nanollose Limited 0.11 18 31 -8 $ 17,121,932.32
MDC Medlab Clinical Ltd 0.165 -15 3 -8 $ 56,458,985.72
JTL Jayex Technology Ltd 0.022 -39 -12 -8 $ 5,483,027.86
VLS Vita Life Sciences.. 1.72 64 -4 -9 $ 90,562,492.64
CDX Cardiex Limited 0.052 -24 -27 -9 $ 50,313,194.15
ALA Arovella Therapeutic 0.041 17 -15 -9 $ 19,717,756.08
DVL Dorsavi Ltd 0.02 -31 11 -9 $ 7,028,651.44
ANP Antisense Therapeut. 0.2 3 -35 -9 $ 134,850,983.38
IMU Imugene Limited 0.5425 34 22 -9 $ 3,139,193,361.15
NTI Neurotech Intl 0.065 12 30 -10 $ 46,713,413.44
PTX Prescient Ltd 0.225 114 -10 -10 $ 148,263,685.14
EPN Epsilon Healthcare 0.099 -38 -36 -10 $ 20,234,229.65
ATH Alterity Therap Ltd 0.026 -4 -13 -10 $ 62,578,739.03
AGH Althea Group 0.255 -33 -15 -11 $ 79,669,910.87
DOC Doctor Care Anywhere 0.5 -40 -30 -11 $ 95,103,218.50
EXL Elixinol Wellness 0.089 -41 -11 -11 $ 29,063,828.19
ACW Actinogen Medical 0.16 129 39 -11 $ 268,313,367.52
PAA Pharmaust Limited 0.097 2 1 -12 $ 30,740,501.15
RHY Rhythm Biosciences 1.7 60 25 -12 $ 362,399,015.06
ACR Acrux Limited 0.11 -24 -8 -12 $ 28,368,033.80
IMM Immutep Ltd 0.4975 -18 -18 -13 $ 435,475,128.51
ONE Oneview Healthcare 0.265 -13 -34 -13 $ 135,739,897.20
CU6 Clarity Pharma 0.9 -20 -13 $ 153,042,712.43
BD1 Bard1 Life Sciences 1.055 -56 -2 -14 $ 96,531,666.00
GTG Genetic Technologies 0.006 -25 -14 -14 $ 55,403,790.86
AC8 Auscann Grp Hlgs Ltd 0.09 -18 -14 -14 $ 40,089,787.01
BPH BPH Energy Ltd 0.041 -54 -33 -15 $ 27,261,694.95
IBX Imagion Biosys Ltd 0.085 -13 18 -15 $ 90,470,137.20
AMT Allegra Orthopaedics 0.17 -32 -26 -17 $ 17,758,064.51
LCT Living Cell Tech. 0.007 -39 -19 -19 $ 4,996,958.58
CPH Creso Pharma Ltd 0.1 -38 -9 -20 $ 120,811,172.00
IVX Invion Ltd 0.0185 106 42 -26 $ 115,384,745.32
SHG Singular Health 0.215 -26 0 -28 $ 15,202,968.27

 

The Sustainable Nutrition Group (ASX:TSN) was the biggest winner, up 24%.

The company recently announced it had partnered with Australian Plant Proteins to develop hemp concentrate and isolates, which would allow TSN to enter the $10.8 billion global plant-based ingredients market with limited capex requirements.

Commercialisation is expected to commence in Q4 FY2022 initially in the Australian and New Zealand markets.

Rhinomed (ASX:RNO) was up 11%, with chairman Ron Dewhurst telling shareholders at the AGM that the sales pipeline for the Rhinoswab looks strong into FY22.

“The product we have developed and have regulatory approval from the FDA in the US, and the TGA in Australia, has now been launched in the market and received initial orders from both the New South Wales and Victorian Government and further, has an identifiable pipeline of opportunities, both domestic and international,” he said.

“The early traction we have received makes us very optimistic about the relevance that the Rhinoswab will have for the company.”

Diagnostics tech company, Proteomics (ASX:PIQ) was up 11%.

The company signed off a two-year distribution deal with Apacor to bring its PromarkerD test for diabetic kidney disease to patients in England, Scotland and Wales.

And Volpara Health (ASX:VHT) was also up 11%.

The company’s FY22 half-year revenues increased significantly from NZ$19.9m in the prior corresponding period (pcp) to NZ$29 million.

Healthcare and life sciences expert Scott Power told Stockhead’s Eddy Sunarto that revenue guidance of NZ$25 million in FY 2022 is conservative.

 

Who flatlined?

Flat was PYC Therapeutics (ASX:PYC).

The company recently completed a key translational milestone for its RNA platform, by determining safe and well-tolerated doses of its co-lead drug candidate, VP-001, in monkeys.

The results are a key step towards toxicity studies scheduled for Q1 2022, that will then support the initiation of a first study in humans.

The human study is set to be the first therapy for patients with Retinitis Pigmentosa type 11 and will address the underlying cause of the disease.

 

Who’s the biggest loser?

The biggest loser was Singular Health (ASX:SHG) which dropped 28%.

The company has ventured out of medical markets by forming GeoVR Pty Ltd, a 50/50 joint venture (JV) with TerraCentric with the objective of commercialising the GeoVR technology.

GeoVR allows for mineral exploration and production data to be visualised in a fully interactive 3D environment.

Singular says the JV allows it to focus on the medical solutions sector, while branching out for diversified revenue sources.

And Invion (ASX:IVX) was down 26%.

The company has entered into conditional agreements with RMW Cho Group to co-develop Photosoft technology for cancer and related diseases (indications) with Invion to gain exclusive distribution rights to the tech in Asia Pacific for the indications.

Invion has also launched a $12 million placement and $3 million share purchase plan at $2.20 per share.